GTH

Genetron Holdings Limited (GTH) | Rumor.io

Genetron Holdings

GTH

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)—

Price to earnings ratio0

Market capitalization0

Earnings per share0

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)0

Social

What share of all stock conversation is about GTH?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% new	0% +0	0% 0

Oct 12

Genetron Holdings Limited ($GTH) has entered into a definitive merger agreement to go private at $1.36 per ADS, with a closing expected in Q1 2024.
The deal values the company at $126M, led by a group led by CEO Sizhen Wang, and will result in the cancellation of the company's ADS.
$GTH shares have rallied in pre-market trading, up 19-26% in response to the news, with trading volume significantly above average.

Generated by AI

Sentiment

Of the messages about GTH that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	—
Bearish	—	—	—	—

Nov 22

Genetron Holdings Limited's ($GTH) price action is similar to early 2021, suggesting a potential for significant growth.
$GTH is considered an undervalued L1, with a strong community and working product, making it a promising investment opportunity.
The token's market capitalization of $35M is seen as a buying opportunity, with some investors expecting a 100x return on their investment.

Generated by AI

Topics

Of the messages about GTH that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	0%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	100%
Technical Analysis	—	—	—	0%

Nov 30

Genetron Holdings Limited (GTH) has signed a deal with AstraZeneca (AZN) for MRD tests for solid tumors in China.
GTH reported a 36.2% revenue increase since 2020 and has recently signed deals with NEO and AstraZeneca.
GTH's unaudited preliminary financial results for the third quarter ended September 30, 2021, showed in-line EPS and beat revenue expectations, with updated full-year guidance.

Generated by AI

Community

Of the messages about GTH, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	0%	0%	0%	13.89%
Newcomers	100%	100%	100%	86.11%

Regulars· Nov 30

Genetron Holdings Limited reported unaudited Q3 2021 results, with GAAP EPS of -$0.04 and revenue of $23.9M, beating estimates.
The company has entered into a co-development agreement with AstraZeneca R&D China for personalized MRD tests for solid tumors.
Genetron Holdings Limited has updated its full-year guidance, following Q3 results.

Newcomers· Apr 9

Newcomers to the GTH asset are focused on its potential for constructive price action, with some speculating that it may have bottomed out.
The company's recent filing of the SEC Form 20-F is being discussed, with some users highlighting its relevance to the asset's growth and opportunities in the healthcare sector.
Investors are also looking at the asset's business applications, with some referencing Mark Cuban's statement on the importance of business applications in generating real money and opportunities.

Generated by AI

Also Discussed

Investors talking about GTH also mention

#	Name	Attention
1	Invesco CurrencyShares Swiss Franc TrustFXF	0%0
2	NGM - NGM Biopharmaceuticals, Inc.	——
3	SPI Energy Co., Ltd.SPI	0%0
4	Exicure Inc.XCUR	0%0
5	Principal Active High Yield ETFYLD	0%0
6	iShares U.S. Financials ETFIYF	0%new
7	EnPro Industries Inc.NPO	0%0
8	Avalon Globocare CorpALBT	0%0
9	AIOZ NetworkAIOZ	0.03%+0.02
10	ARGO - Argo Group International Holdings, Ltd.	——